Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07367880
Recruiting Observational

The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)

NCT07367880 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Grenoble
Phase
Observational
Started
2026-02-23
Last updated
2026-05-26

Condition(s) studied

Alzheimer s Disease

Investigational drug(s) / intervention(s)

Identification and naming task

Identification and naming task: Task of identification and naming of landmarks and celebrities

Study summary

The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.

Eligibility

Sex
ALL
Min age
50 Years
Max age
95 Years
Healthy volunteers
Accepted
Inclusion criteria : * Alzheimer's disease: * Age ≥ 50 years and older * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011. * Score 18≤ MMSE ≤26 * Controls: * Age ≥ 50 years and older * MMSE score ≥ 26 For all subjects * No objection from the participant Exclusion criteria * Alzheimer's disease: * Persons referred to in Articles L1121-5 to L1121-8 of the CSP * Controls: * Memory complaints * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects * Significant neurological or psychiatric history * Taking psychotropic medication (neuroleptics) * Poor command of the French language, comprehension difficulties * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.) * Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Grenoble Alpes Grenoble France Recruiting

More University Hospital, Grenoble trials in France

Down Syndrome, Physical Activity and Sleep Apnea Recruiting
Osteosynthesis of Fibula Fractures With a Locked Thin Plate Starting soon
Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa Recruiting
Preparation and Feasibility of Exams for Expected Studies Recruiting
Effectiveness of a Communication Training Program in Improving the Handling of Calls for Suspected Cardiac Arrest at SAMU-Centre 15. Starting soon

Other trials for the same condition

Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease Starting soon
Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease Recruiting
Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07367880 on ClinicalTrials.gov ↗ ← All trials in France